Open Doors to the Asian Market: Seoul Bio Hub-Celltrion Launches ‘Global Open Innovation’ for U.S. Startups

SEOUL, SOUTH KOREA, Sept 17, 2025 – (ACN Newswire) –Seoul’s bio start-up center ‘Seoul Bio Hub’ and international pharmaceutical leader ‘Celltrion’ have actually signed up with forces to introduce the ‘2025 Seoul Bio Hub-Celltrion Global Open Innovation (GOI)’ program. This program exceeds an easy competitors, working as a platform developed to assist U.S. start-ups effectively develop themselves in the Asian market.

< img src ="https://photos.acnnewswire.com/20250917.SH.jpg" alt width ="650" height ="928">

This GOI targets U.S.-based bio and medical start-ups, with business developed within the previous 7 years qualified to use. The recruitment locations include all innovations ideal for cooperation with Celltrion, consisting of antibodies, peptides, little particles, solutions, and cell and gene treatments.

The application due date is September 30, 2025. The choice procedure will continue in the following order:

• Main file examination
• Innovation evaluation
• Secondary discussion examination.

The 2 lastly picked business will get personalized follow-up assistance and gain chances to broaden into international markets through partnership with Celltrion, leveraging South Korea’s ingenious community and international abilities.

A Seoul Bio Hub representative specified, “This program will serve as a bridgehead that goes beyond simple space support, enabling U.S. startups to rapidly grow in the Asian market by leveraging Seoul’s excellent clinical infrastructure and research environment.”

A Celltrion agent revealed, “Based on Celltrion’s capabilities and know-how accumulated across the entire pharmaceutical industry process including R&D, production, and sales, we will support promising U.S. startups to successfully enter the Asian market and create synergy with our company.”

South Korea has actually developed itself as a bio center leading the worldwide market with clear mathematical proof. According to worldwide consulting company Intralink, South Korea’s biopharmaceutical market is valued at roughly $22 billion, ranking 13th internationally.

Furthermore, marketing research company Grand View Research anticipates that South Korea’s biotechnology market will grow to $81.6 billion (roughly 110 trillion KRW) by 2030, representing a yearly typical development rate of 18.3%.

Personal financial investment is likewise active. From 2020 to 2022, R&D and center financial investments tape-recorded a yearly typical development rate of 21.6%. This shows that South Korea is not simply a prospective market, however a quickly growing development environment.

According to ClinicalTrials.gov, the worldwide medical trial database, Seoul has actually regularly kept a leading position amongst significant worldwide cities in the variety of brand-new scientific trials over the previous years.

South Korea’s Ministry of Health and Welfare has actually set ‘Achieving Global 3rd Place in Clinical Trials’ as a policy goal through the ‘3rd Five-Year Plan for the Pharmaceutical and Bio Industry (2023-2027)’. In 2025, it raised an overall of over 386.6 billion KRW through the ‘Bio Health Mega Fund’ and is actively supporting ingenious business’ medical trials and commercialization through the nationwide integrated bio huge information building and construction task and AI, bio health regulative sandboxes.

Seoul Bio Hub is a bio start-up assistance company developed by Seoul City in 2017. It supplies 251 pieces of shared lab devices and inexpensive renter area at 10% of the expense compared to significant locations in Seoul. Since May 2025, it has actually supported 322 start-ups and brought in an overall of 576 billion KRW in follow-up financial investment, showing its capacity for success.

Celltrion is South Korea’s worldwide thorough biotechnology business that established the world’s very first antibody biosimilar ‘Remsima’. The business carries out the whole procedure from research study and advancement to approval, production, and sales, providing premium biopharmaceuticals to over 100 nations worldwide. Based upon first-rate research study and production facilities, it adds to broadening worldwide access to pharmaceuticals and continues to support and team up with appealing start-ups through active open development techniques.

For comprehensive details concerning program applications and queries, please gain access to LinkedIn, look for ‘Seoul Bio Hub’, and inspect the ‘2025 Seoul Bio Hub-Celltrion Global Open Innovation’ recruitment statement published on the main business page.

About Seoul Bio Hub

https://www.seoulbiohub.kr/front/user/engmain.do

Facility Date: October 30, 2017

Running Entity: Established by Seoul City/ Joint operation by KIST and Korea University

Place: 117-3 Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea

Function: Growth and commercialization assistance for early-stage bio and health care start-ups under 10 years

Renter Companies (As of June 2025): Total 126 business (Digital Health 42 business (33.3%), Pharmaceuticals 61 business (48.5%), Medical Devices 23 business (18.2%))

Facilities: Laboratories, office, conference room, meeting room, research study devices (249 gadgets, 109 types, around $8 million scale)

Research Study and Human Resource Network (Regional): Approximately 7,000 PhD-level workers, around 120,000 college student, $1.13 billion in research study financing, connections with 12 universities and research study organizations and 7 medical facilities

Significant Support Programs:

• IR matching and financial investment linkage
• Specialist consulting and CEO education
• Hospital-linked medical and information programs
• Open development with domestic and worldwide pharmaceutical business

About Celltrion

https://www.celltrion.com/en-us

Facility Date: February 26, 2002

Place (Headquarters): 23 Academy-ro, Yeonsu-gu, Incheon Metropolitan City, Republic of Korea

Organization Areas and Major Products (Services)

Having Differentiated Integrated Solutions Across the Entire Biopharmaceutical Business Process

• Remsima: World’s very first monoclonal antibody biosimilar (TNF-α inhibitor)
• Herzuma: Trastuzumab biosimilar for breast and stomach cancer treatment
• Truxima (CT-P10): Rituximab biosimilar (lymphoma, rheumatoid arthritis, and so on)
• Several items consisting of Zymfentra, Yuflyma, Vegzelma, Steqeyma, Avtozma are under international approval and commercialization

No of Employees: Approx. 3,003 (As of June 30, 2025)

Media Contact
Brand Name: SEOUL BIO HUB
Contact: Lee Yoon Jin
Phone: +82 02-2200-3345
Site:(KOR)https://www.seoulbiohub.kr/front/user/main.do;
(ENG) https://www.seoulbiohub.kr/front/user/engmain.do

Subject: Press release summary